3차 재발 환자도 살리는 면역 개조 암 치료법 - 김진석 교수 (연세대 세브란스병원 혈액내과)

#Bio #Cancer #CancerTreatment #CART #CARTTherapy #CellTherapy #Medical #Aging #Health #Immunity #ProfessorParkJungHo [Content summarized via AI] 🧬 A New Breakthrough in Cancer Treatment: CAR-T Cell Therapy CAR-T cell therapy is a personalized immunotherapy that involves manipulating a patient's immune cells, specifically T cells, outside the body to attack only cancer cells, and then re-injecting them into the body. While conventional anticancer treatments attack both cancer and normal cells, CAR-T cell therapy is designed to recognize specific markers on the surface of cancer cells, allowing it to selectively attack the cancer. Currently, it is most actively used in the treatment of blood cancers (particularly lymphoma and multiple myeloma), and is often applied as a third-line treatment for patients who have failed conventional treatments two or more times. It is evaluated as a groundbreaking treatment method, as it has confirmed a long-term survival or cure rate of over 30% in patient groups where the survival probability was previously around 10% with conventional treatments. However, the treatment is very expensive, exceeding 300 million won, and requires management at specialized medical institutions due to the potential for immune response side effects, such as cytokine storms, during the process. Furthermore, because it requires characteristic markers of cancer cells, it is currently used primarily for hematological cancers, and its application to solid tumors such as gastric and liver cancer is still in the research stage. As research on immunotherapy advances rapidly worldwide, new technologies such as improved CAR-T cells, CAR-NK cell therapy, and bispecific antibody therapy are emerging. As clinical trials and technological advancements continue, the likelihood of more cancer patients benefiting from treatment is increasing, and a trend is emerging in the cancer treatment paradigm shifting from a focus on conventional anticancer drugs to one centered on immunotherapy and cell therapy. ⏱ Timecode 00:00 ~ 02:48 │ Types and Characteristics of Blood Cancer (Lymphoma · Multiple Myeloma) 02:48 ~ 04:21 │ Explanation of the Principles of CAR-T Cell Therapy 04:21 ~ 06:06 │ Current Status of Domestic Application and Target Patients 06:06 ~ 07:59 │ Effect of Improved Survival Rates Compared to Conventional Treatment 07:59 ~ 09:58 │ Treatment Costs and Health Insurance Coverage Structure 09:58 ~ 12:16 │ Reasons for Focusing Treatment on Blood Cancer and Limitations of Solid Tumors 12:16 ~ 15:43 │ Necessity of Clinical Trials and Significance of Participation 15:43 ~ 18:07 │ Side Effects (Cytokine Storm) and Management Methods 18:07 ~ 22:08 │ Next-Generation Cell Therapy Technologies (CAR-NK, etc.) 22:08 ~ 26:13 │ mRNA-Based In Vivo CAR-T Development Research 26:13 ~ 31:29 │ The Era of Immunotherapy and a New Anti-Cancer Paradigm 31:29 ~ 42:41 │ Future Prospects for Cancer Treatment and Patient Advice 💡 Key Point in One Line CAR-T cell therapy is a next-generation personalized treatment that directly attacks cancer using a patient's own immune cells. It is an innovative technology that significantly increases the survival chances of blood cancer patients who have failed conventional treatments. ※ Host: Park Jung-ho, Professor at Myongji University ◈ Broadcast Schedule YouTube: Daily 10:30 AM ~ 11:20 AM Radio: MBC Standard FM Daily 10:05 PM ~ 11:00 PM